Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Indivior ( (GB:INDV) ) is now available.
Indivior announced a delay in the FDA’s final review of proposed label changes for its product SUBLOCADE, specifically for rapid initiation protocol and alternative injection sites. Although the FDA has accepted the proposed label with no outstanding issues, the delay may impact Indivior’s timeline for implementing these changes, potentially affecting its market strategy and stakeholder expectations.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, specializing in the development and manufacturing of addiction treatment products. One of its primary products is SUBLOCADE, a buprenorphine extended-release injection designed for the treatment of opioid use disorder.
YTD Price Performance: -25.29%
Average Trading Volume: 259,548
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £950.7M
Find detailed analytics on INDV stock on TipRanks’ Stock Analysis page.
